Therapeutic blockade of HMGB1 reduces early motor deficits, but not survival in the SOD1G93A mouse model of amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS) is a fatal and rapidly progressing neurodegenerative disease without effective treatment. The receptor for advanced glycation end products (RAGE) and the toll-like receptor ...

Source: Journal of Neuroinflammation - February 19, 2019 Category: Neurology Authors: John D. Lee, Ning Liu, Samantha C. Levin, Lars Ottosson, Ulf Andersson, Helena E. Harris and Trent M. Woodruff Tags: Research Source Type: research